There is no translation available.
Would you invest in a US biotech company... ?
- with a 2017E P/E of 6.4x and a debt/equity ratio of 1,29
- paying a dividend yield of nearly 2.8 %
- its current book-value is estimated at 4.6x
- its EBIT margin at 58 % and net margin at 44 %
- its cash-flow and its free cash-flow are largely positive
Please meet one of our Partners to be informed of the latest investment opportunities.
During a meeting, we will define your investment and your risk profile as to suggest the best solution according to your affinities and needs.
For contact : This email address is being protected from spambots. You need JavaScript enabled to view it.
